<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>619C89 is a use-dependent <z:chebi fb="1" ids="29101">Na+</z:chebi> channel <z:chebi fb="68" ids="48706">antagonist</z:chebi> that decreases the release of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The efficacy of this drug in reducing infarction volume 72 h after occlusion of the middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) for 2 h in rats (n = 93) was determined by analysis of TTC-stained coronal section of the brain </plain></SENT>
<SENT sid="2" pm="."><plain>Doses of 10, 20, 30 and 50 mg/kg of study drug given i.v. prior to <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion significantly (P &lt; 0.05-0.01) reduced infarction volume in cortex compared to vehicle controls </plain></SENT>
<SENT sid="3" pm="."><plain>Only the 50 mg/kg dose reduced infarction volume in the striatum (P &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>Administration of 50 mg/kg of 619C89 30 and 60 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reduced cortical infarction volume (P &lt; 0.05), but there was no effect when the drug was given 5 min after reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>No post-treatment regimen reduced striatal infarction volume </plain></SENT>
<SENT sid="6" pm="."><plain>These results confirm the neuroprotective effects of 619C89 in temporary focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>